ArticlePloS one2026
Changes in pneumococcal vaccine coverage in the Canadian Longitudinal Study on Aging (CLSA): An analysis based on the 2018-2021 follow-up 2 survey.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPneumococcal vaccination is recommended for older adults and individuals with chronic medical conditions (CMC) due to the high risk of invasive pneumococcal disease in these groups. Despite this, vaccination coverage in Canada remains below the national target of 80%, to be achieved by 2025. We conducted a new analysis of recently released data from the Canadian Longitudinal Study on Aging (CLSA), aimed at providing estimates of pneumococcal vaccine coverage from 2018-2021 among eligible adults, identifying sociodemographic disparities, and exploring changes over time since 2015.
methodsThe CLSA, a nationally representative cohort launched in 2011, recently released data collected during the second follow-up visit (FUP2; 2018-2021). We conducted a cross-sectional analysis of participant self-reported pneumococcal vaccination status, stratified by sociodemographic characteristics, receipt of influenza vaccine in the previous 12 months, and contact with family doctor in the previous 12 months. Logistic regression was used to identify factors associated with being newly vaccinated for pneumococcal disease as reported during FUP2 compared with three years earlier during follow-up 1 (FUP1; 2015-2018). We previously reported pneumococcal vaccination estimates for 2015-2018.
resultsOnly 56.8% (95% CI: 55.8-57.7%; n = 10,530) of eligible study participants aged 65 years and older and 19.3% (95% CI: 18.1-20.5%; n = 4,055) of those aged <65 years with at least 1 chronic medical condition reported having received the pneumococcal vaccine when surveyed between 2018-2021. Males, rural residents, and individuals in certain provinces reported lower vaccination rates. Compared to three years prior, 28.4% of participants aged 65 years and older and 11% of participants aged <65 years with at least one CMC reported being newly vaccinated. Higher odds of being newly vaccinated were observed among individuals who reported having received influenza vaccination in the previous 12 months in both age groups.
conclusionsPneumococcal vaccine coverage among Canadian adults aged 65 and older enrolled in the CLSA increased by only 2% between 2015-2018 and 2018-2021, and no changes were observed among those under the age of 65 with underlying conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.